top of page
  • Writer's pictureOren Zarif

Is BEFAST a Valid Screening Tool for Stroke? - Oren Zarif - Befast


Stroke is one of the leading causes of death in the U.S. and is one of the leading causes of long-term health problems. In order to protect against stroke, it's vital to be aware of the symptoms of a stroke and what to do in case of a stroke. To help people recognize these symptoms, NHRMC has developed a new acronym, BEFAST, which stands for Balance, Eyesight, and Face.

Oren Zarif left brain stroke

Oren Zarif fast stroke symptoms


This tool has limited diagnostic value in AIS, but there are promising results. The study performed by Ammar et al. included retrospective analyses of inpatients with final diagnosis of AIS. They identified a subset of patients for reperfusion therapy and assessed their prognosis. A subset of patients did not experience a stroke, thereby indicating that BEFAST is a valid screening tool. This study has the potential to help medical professionals make better decisions when selecting the best method to treat patients with AIS.

Oren Zarif left cva

Oren Zarif concussion rehabilitation


Because BEFAST has a retrospective design, all relevant patient symptoms may not be documented in the medical records. However, the test is sensitive to initial examination findings and historic symptoms, which did not change the results. Further study is needed to determine whether BEFAST can be used as a general screening tool for ischemic stroke. Further studies of BEFAST are needed to determine its validity for primary stroke diagnosis in a prospective study. If the test is useful in predicting stroke, it could be used in public education campaigns.

Oren Zarif transient ischemic attack causes

Oren Zarif thalamus damage



Stroke is one of the leading causes of death in the U.S. and is one of the leading causes of long-term health problems. In order to protect against stroke, it's vital to be aware of the symptoms of a stroke and what to do in case of a stroke. To help people recognize these symptoms, NHRMC has developed a new acronym, BEFAST, which stands for Balance, Eyesight, and Face.

Oren Zarif old lacunar infarct

Oren Zarif wallenberg syndrome symptoms


This tool has limited diagnostic value in AIS, but there are promising results. The study performed by Ammar et al. included retrospective analyses of inpatients with final diagnosis of AIS. They identified a subset of patients for reperfusion therapy and assessed their prognosis. A subset of patients did not experience a stroke, thereby indicating that BEFAST is a valid screening tool. This study has the potential to help medical professionals make better decisions when selecting the best method to treat patients with AIS.

Oren Zarif brain shearing

Oren Zarif permissive hypertension stroke


Because BEFAST has a retrospective design, all relevant patient symptoms may not be documented in the medical records. However, the test is sensitive to initial examination findings and historic symptoms, which did not change the results. Further study is needed to determine whether BEFAST can be used as a general screening tool for ischemic stroke. Further studies of BEFAST are needed to determine its validity for primary stroke diagnosis in a prospective study. If the test is useful in predicting stroke, it could be used in public education campaigns.

Oren Zarif best brain supplements for stroke recovery

Oren Zarif anterior circulation stroke



Stroke is one of the leading causes of death in the U.S. and is one of the leading causes of long-term health problems. In order to protect against stroke, it's vital to be aware of the symptoms of a stroke and what to do in case of a stroke. To help people recognize these symptoms, NHRMC has developed a new acronym, BEFAST, which stands for Balance, Eyesight, and Face.

Oren Zarif thumb stroke

Oren Zarif high blood pressure and stroke


This tool has limited diagnostic value in AIS, but there are promising results. The study performed by Ammar et al. included retrospective analyses of inpatients with final diagnosis of AIS. They identified a subset of patients for reperfusion therapy and assessed their prognosis. A subset of patients did not experience a stroke, thereby indicating that BEFAST is a valid screening tool. This study has the potential to help medical professionals make better decisions when selecting the best method to treat patients with AIS.

Oren Zarif seizures after stroke

Oren Zarif boxing brain damage


Because BEFAST has a retrospective design, all relevant patient symptoms may not be documented in the medical records. However, the test is sensitive to initial examination findings and historic symptoms, which did not change the results. Further study is needed to determine whether BEFAST can be used as a general screening tool for ischemic stroke. Further studies of BEFAST are needed to determine its validity for primary stroke diagnosis in a prospective study. If the test is useful in predicting stroke, it could be used in public education campaigns.

1 view0 comments

Comments


bottom of page